NanOlogy
  • Home
  • About
  • Technology
  • Development
    • Investigational Drugs
    • Pipeline
    • Clinical Trials
  • News & Publications
    • Recent News Highlights
    • Press Release Archives
    • NanOlogy In the News
    • Presentations & Publications Archive
  • Contact Us
    • Partnering Opportunities
    • Physicians and Patients
Post placeholder image
February 23, 2026 in NanOlogy in the News

CEOCFO Magazine: NanOlogy – Advancing their PURCISION™ Technology using Intratumoral Therapy to Solve the Toxicity Problem when Treating Cancer

NanOlogy 0 Like Post Comments Off on CEOCFO Magazine: NanOlogy – Advancing their PURCISION™ Technology using Intratumoral Therapy to Solve the Toxicity Problem when Treating Cancer
Read More
NanOlogy

NanOlogy investigational drugs have not yet been proven to be safe and effective in accordance with the requirements of the U.S. FDA and are not approved by FDA or any other jurisdiction for commercial distribution. NanOlogy, NanoPac, and NanoDoce are trademarks of NanOlogy, LLC.    Purcision is a trademark to CritiTech, Inc.  © NanOlogy LLC      Legal